Gender bias in lipid assessment and treatment following percutaneous coronary intervention

Journal of Gender-Specific Medicine

Volumn 6, Issue 3, 2003, Pages 21-26

  Corbelli, Jennifer A ^a   Corbelli, John C ^a   Bullano, Michael F ^b   Willey, Vincent J ^b   Cziraky, Mark J ^b   Banks, Lois D ^a   Cooke, Beth E ^a   Galla, Ann M ^a   Berchou, Kevin A ^a   Drury, Christopher J ^b  

^a Buffalo Cardiol and Pulmon Assoc   (United States)

^b HEALTHCORE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY SURGERY; DATA BASE; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREOPERATIVE EVALUATION; PRIMARY MEDICAL CARE; PRIVATE PRACTICE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOLOGY; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HEMATOLOGIC TESTS; HUMANS; LIPIDS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEW YORK; PHYSICIAN'S PRACTICE PATTERNS; POSTOPERATIVE CARE; PREJUDICE; RETROSPECTIVE STUDIES; TRIGLYCERIDES; WOMEN'S HEALTH;

EID: 0041885015     PISSN: 15237036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
3. Prevention of cardiovascular events and death with provostatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
4. Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI post coronary artery bypass graft clinical trial. Circulation 1999;99:3241-3247.
5. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-436.
6. Pearson TA, Myerson M. Treatment of hypercholesterolemia in women: Equality, effectiveness, and extrapolation of evidence. JAMA 1997;277:1320-1321.
7. Isles CG, Hole DJ, Hawthorne VM, Lover AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley Survey: Comparison with men. Lancet 1992;339:702-706.
8. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias [POSCH). N Engl J Med 1990;323:946-955.
9. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993;119:969-976.
10. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
11. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
13. Pearson TA, Kris-Etherton PM. Attainment of low-density lipoprotein (LDL) cholesterol goals in primary care practice: Success depends on baseline level of risk. Circulation 1996;94:1-177.
14. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996;75:334-342.
15. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
16. Cowley WJ, Mullin SM, Kelsey SF, et al. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry. Circulation 1985;71:90-97.
17. Kelsey SF, James M, Holubkov AL, et al. Results of percutoneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993;87:720-727.
18. Malenka DJ, O'Connor GT, Quinton H, et al. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty: A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. Circulation 1996;94(9 suppl):1199-11104.
19. Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: Evidence for a higher mortality in younger women. Circulation 2002;105:1176-1181.
20. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: Does evidence change practice? Arch Intern Med 2001;161:183-188.
21. Ayanian JZ, Landrum MB, McNeil BJ. Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med 2002;162:1013-1019.
22. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
23. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-436.
24. Jacobs AK, Johnston JM, Haviland A, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2002;39:1608-1614.
25. Kane JP, Malloy JM, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
26. Sacks FM, Pfeffer MA, Moye L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991;68:1436-1446.
27. Castelli WP. Cardiovascular disease in women. Am J Obstet Gynecol 1988;158:1553-1560, 1566-1567.
28. Vaccarino V, Horwitz RI, Meehan TP, et al. Sex differences in mortality after myocardial infarction: Evidence for a sex-age interaction. Arch Intern Med 1998;158:2054-2062.
29. Vaccarino V, Krumholz HM, Yarzebski J, et al. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med 2001;134:173-181.
30. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction: National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999;341:217-225.
31. Alter DA, Naylor CD, Austin PC, Tu JV. Biology or bias: Practice patterns and long-term outcomes for men and women with acute myocardial infarction. J Am Coll Cardiol 2002;39:1909-1916.